Showing results (591-600 of 623) with videos related to
Sort By:
Pageof 63
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.Nature Immunology|December 5, 2024
Pyroptotic cell corpses are crowned with F-actin-rich filopodia that engage CLEC9A signaling in incoming dendritic cellsCaroline L Holley, Mercedes Monteleone, Daniel Fisch, et al.JAMA Oncology|December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.Proceedings of the National Academy of Sciences of the United States of America|February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapyXin Hong, Ryan J Sullivan, Mark Kalinich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.Genome Research|May 5, 2001
From first base: the sequence of the tip of the X chromosome of Drosophila melanogaster, a comparison of two sequencing strategiesP V Benos, M K Gatt, L Murphy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.Pageof 63